Platelet Aggregation

Inhibition of platelet aggregation using different regiments in patients with STEMI undergoing PCI.

Cangrelor resulted in inferior platelet aggregation inhibition compared with tirofiban in patients with STEMI who were undergoing PCI, the FABOLUS-FASTER study found.

PARIS — When added to dual antiplatelet therapy, vorapaxar reduced platelet-mediated thrombogenicity without impacting clot kinetics in patients with and without diabetes, according to results from the OPTIMUS-5 study presented at the European Society of Cardiology Congress.